摘要
细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂联合内分泌治疗已成为激素受体阳性(HR^(+))、人类表皮生长因子受体-2阴性(HER2^(-))乳腺癌患者的晚期一线及二线标准治疗方案。尽管CDK4/6抑制剂可实现有效的疾病控制,但对于晚期乳腺癌患者最终仍会因耐药出现疾病进展。目前CDK4/6抑制剂相关耐药机制尚不完全清楚,同时治疗失败后的最佳治疗策略仍是一个亟待解决的问题。本文就CDK4/6抑制剂的潜在耐药机制和后续治疗策略的最新研究进展做一综述。
Cyclin-dependent kinase 4/6(CDK4/6)inhibitors plus endocrine therapy have been used as standard first-or second-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer.Although CDK4/6 inhibitors provide excellent control in patients with hormone receptor-positive advanced breast cancer,due to drug resistance cancer progression will eventually occur as treatment proceeds.At present,the resistance mechanism of CDK4/6 inhibitors is not fully understood,and the optimal treatment strategy after failure of CDK4/6 inhibitors remains an urgent problem.This review summarized the potential resistance mechanism and subsequent treatment strategies of CDK4/6 inhibitors.
作者
王蕾
杨思原
张季
聂建云
WANG Lei;YANG Si-yuan;ZHANG Ji;NIE Jian-yun(School of Clinical Oncology,Kunming Medical University,Kunming 650000;Yunnan Cancer Hospital,The Third Affiliated Hospital of Kunming Medical University,Kunming 650000)
出处
《中南药学》
CAS
2024年第4期1030-1036,共7页
Central South Pharmacy
基金
国家自然科学基金项目(No.81960479,No.81760480)
云南省科技计划项目(No.2019FA040,No.202201AY070001-153)。
